Joshua Martin, MD
Physical Medicine & Rehabilitation · Potomac, MDNPI 1992169965
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $373 and has fallen 80.4% since, to $73 in 2025.
Across 51 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$156
- Scilex Pharmaceuticals Inc.$109
- DJO, LLC$72
- Arteriocyte Medical Systems, Inc.$68
- Fidia Pharma USA Inc.$62
- IBSA Pharma Inc.$60
- plus $386 from 13 others
What the payments were for
- Food & beverage$912100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $156 |
| Scilex Pharmaceuticals Inc. | 8 | $109 |
| DJO, LLC | 1 | $72 |
| Arteriocyte Medical Systems, Inc. | 1 | $68 |
| Fidia Pharma USA Inc. | 3 | $62 |
| IBSA Pharma Inc. | 5 | $60 |
| Pacira Therapeutics, Inc. | 4 | $59 |
| Arbor Pharmaceuticals, Inc. | 3 | $42 |
| Bioventus LLC | 1 | $38 |
| Redhill Biopharma Inc. | 3 | $36 |
| Smith+Nephew | 1 | $33 |
| Johnson & Johnson | 1 | $30 |
| Pacira Pharmaceuticals Incorporated | 1 | $27 |
| Amgen | 1 | $26 |
| Lilly USA, LLC | 2 | $24 |
| Novo Nordisk | 1 | $22 |
| Orthogenrx Inc. | 1 | $20 |
| Vertex | 1 | $17 |
| Pfizer | 1 | $12 |
How this compares
$912 in reported general payments places this provider in the 75th percentile of 202 physical medicine & rehabilitation providers in Maryland.
See all physical medicine & rehabilitation providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 28 | $358 |
| Tramadol Hcl | 24 | $68 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Potomac
- David ReeceBethesda$719K
- Gurtej SinghCatonsville$205K
- Akhil ChhatreBaltimore$169K
- Justin WassermanBethesda$51K
- Vivek SindhiGlen Burnie$33K
- Inai MkandawireOwings Mills$23K
- Cheryl MejiaHagerstown$20K
- Ronald ShinBaltimore$19K
- Mustafa BroachwalaBaltimore$17K
- Suhas BadarinathMount Airy$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.